2018 American Transplant Congress
Enrichment of Endogenous Donor-Reactive Tregs in the Spleen and Graft during Transplantation Tolerance is the Result of Treg Proliferation and Conversion from Tconv
Surgery and Medicine, University of Chicago, Chicago, IL.
Foxp3+ regulatory T cells (Tregs) are critical mediators of immune tolerance and are absolutely required for allograft tolerance in animal models. In addition, clinical trials…2018 American Transplant Congress
The Infusion with a Difference: Patient Experiences with Belatacept
Yale University, New Haven, CT.
Introduction: The results of the BENEFIT trial led to the FDA approval of the novel anti-rejection agent belatacept (bela) in 2011. In addition to its…2018 American Transplant Congress
Inhibition of IL-1R1 Signaling Delays Costimulation Blockade–Resistant Allograft Rejection by Preventing CD8 TEM Expansion
Department of Surgery, Emory University, Atlanta, GA.
The clinical utilization of Costimulaiton Blockade (CoB) led to improved long-term patient outcomes, but wider adoption of is hampered by increased rates of acute cellular…2018 American Transplant Congress
Circulating T Follicular Helper Cells Expand Following Transplantation and Exhibit a CD44hi Phenotype That Correlates with Peak Germinal Center Alloreactivity
Emory Transplant Center, Atlanta.
It is increasingly well-recognized that donor-specific antibodies (DSA) play a significant role in the development of chronic rejection and fibrosis that contribute to late renal…2018 American Transplant Congress
CFZ533, a New Anti-CD40 mAB Demonstrates Comparable Efficacy and Better Renal Function versus Tacrolimus in De-Novo CNI-Free Kidney Transplantation
1CFZ533 Study Group, Basel, Switzerland; 2Novartis Pharma, Basel, Switzerland.
Purpose: To assess the potential of CFZ533 as primary immunosuppressant in a calcineurin(CNI)-free regimen in de novo kidney transplant (KTx) patients(pts).Method: CFZ533 is a new,…2018 American Transplant Congress
Preemptive B Cell Depletion Modulates Pathogenic Alloimmunity Associated with Selective Non-Activating CD28 Blockade
Purpose: Because anti-donor alloantibody (alloAb) elaboration is associated with chronic allograft rejection, peri-transplant B cell depletion is being explored to modulate pathogenic alloimmunity. Here, we…2018 American Transplant Congress
Recipient IFNAR1 Signaling Supports Costimulation Independent Rejection by Promoting T Cell Activation
Department of Surgery, Emory University, Atlanta, GA.
Costimulation blockade (CoB) is a promising strategy for more targeted/less toxic transplant immunosuppression which has led to the first improvement in long-term outcomes for transplant…2018 American Transplant Congress
Rhesus-Specific Anti-Thymocyte Globulin as an Adjuvant to Costimulatory-Blockade-Based Immunotherapy
Background Belatacept targets de novo alloimmune responses with minimal off target effects in renal transplantation, though adjuvant therapy is required to control costimulation-blockade resistant rejection…2018 American Transplant Congress
Ex Vivo Expanded Regulatory T Cells Combined with Short-Term Costimulation Blockade Prevent Rejection of Vascularized Composite Allografts
[Background] Reconstructive transplantation represents a valid therapeutic option after devastating tissue loss. Routine clinical application, however, is hampered by the toxicity of long-term maintenance immunosuppression.…2018 American Transplant Congress
Belatacept-Refractory CD8+CD28–CD38hi Effector/Memory T Cells Are Targeted by mTOR Inhibition Leading to a Preferential Loss of CD40L
Calcineurin inhibitors (CNIs) and corticosteroids (CSS) have substantial untoward side effects, most notably nephrotoxicity. Consequently, the FDA approved belatacept for maintenance immunosuppression. We recently completed…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 30
- Next Page »